webinar register page

Webinar banner
[FREE TALK] How to translate your oncology target into a preclinical candidate - Part 2
Join us live to further discuss how to de-risk your oncology drug discovery programs.

Based on your feedback from the last NUVISAN talk, we designed a follow-up talk focusing on the obstacles you may encounter when developing a novel preclinical compound.

By going deeper into recent drug discovery programs, we will exemplify how NUVISAN approaches these challenges.

In our examples, we will show how to identify novel small molecule inhibitors by a phenotypic screening approach and how to deconvolute the underlying target. Furthermore, we will show how to come to a deeper understanding of the Mode of Action of a novel compound class. Finally, we will show how to assess the therapeutic potential and the PK/PD relationship of novel compounds in vivo.

In a Q&A session following the presentation, 15 minutes will be allocated to further discuss.

Interested in learning how to accelerate your drug discovery program in oncology and lower your attrition rate?

In this 45-minute presentation, Dr. Martin Lange, Head of Translational Research, and Dr. Carlo Stresemann, Head of Therapeutic Oncology Research, will cover:

• Target deconvolution of novel compounds
• Elucidating mechanism of actions (MoA) of novel compounds
• In vivo profiling of novel compounds
• Live Q&A Session

[Can't join?] Don't worry, register anyway, the slides and recording will be sent to you after the webinar.
NUVISAN Pharma Services
* Required information
Loading

Speakers

Dr. Carlo Stresemann
Head of Therapeutic Oncology Research @Nuvisan
Carlo Stresemann is a specialist on pharmacology, target validation and chemical biology in cancer. Prior to joining NUVISAN in 2020, he gathered his experience working for 12 years within research pharmacology at BAYER AG, where he started as a lab head leading drug discovery programs from early target validation until clinical development. He pioneered the field of epigenetic research at BAYER but also led projects targeting different other cancer pathways including survival signalling, metabolism, apoptosis, and cancer stem cells. Carlo is a Biologist by training and graduated from Heidelberg University. He holds a PhD since 2008 for studying DNA methylation changes and DNA methyltransferase inhibitors as therapeutic approach in cancer at the German Cancer Research Center (DKFZ) in Heidelberg. At Nuvisan Carlo leads the Therapeutic Oncology Research group.
Dr. Martin Lange
Head of Translational Research @Nuvisan
Martin Lange is a biologist by training with more than 10 years of experience in the pharmaceutical industry. He graduated from the University of Marburg, Germany, followed by a term as a Junior Researcher at the Victor Chang Cardiac Research Institute in Sydney, Australia. He obtained his PhD for work on molecular mechanisms of heart development at the Max Planck Institute for Molecular Genetics in Berlin, Germany. In his Post-Doc at the Centre for Genomic Regulation in Barcelona, Spain, he studied gene regulatory mechanisms of embryonic stem cells. Martin joined Bayer Pharma in 2011, where he established a living biobank of 3-dimensional patient-derived cancer organoid models. In his role as lab head in Bayer´s Oncology research, he specialized in Lead Optimization of Small Molecule Inhibitors and Biomarker identification. In his role as preclinical project lead, he helped to advance programs into clinical development.